• Enhanced algorithm with new 100 mg/dL Target Glucose and improved alarm handling helps users improve time in range and stay in Automated Mode longer
  • Omnipod 5 is now compatible with Abbott's Libre 3 Plus sensor in U.S., giving users more choice in how they manage their diabetes
  • New features are designed to improve outcomes, reduce diabetes burden, and unlock barriers to AID technology to meet the needs of people with diabetes

Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the U.S. rollout of new algorithm enhancements for the Omnipod 5 Automated Insulin Delivery (AID) System. The updates follow FDA 510(k) clearance in December 2025. Omnipod 5 is also now compatible in the U.S. with Abbott's Libre 3 Plus sensor, expanding choice for people with diabetes.